Erythropoietin in animal models of inflammation

Silva, Inês; Alípio, Carolina; Pinto, Rui; Mateus, Vanessa

Publication

Erythropoietin in animal models of inflammation

2021-05Conference object

dc.contributor.author	Silva, Inês
dc.contributor.author	Alípio, Carolina
dc.contributor.author	Pinto, Rui
dc.contributor.author	Mateus, Vanessa
dc.date.accessioned	2024-12-02T12:00:33Z
dc.date.available	2024-12-02T12:00:33Z
dc.date.issued	2021-05
dc.description	H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020.	pt_PT
dc.description.abstract	Background: Erythropoietin binds to the erythropoietin receptor to promote the proliferation and differentiation of red blood cells. This hypoxia-induced hormone is produced in adult kidneys with erythropoietin and non-erythropoietic effects. Since current anti-inflammatory therapies are not safe, erythropoietin emerges as a new pharmacological approach reverting the mechanism of inflammation with apparently lower toxicity. AIM: Evaluate the potential anti-inflammatory effect of erythropoietin observed in animal inflammatory disease models. Methods: A systematic review followed PRISMA statements in the electronic database MEDLINE via the PubMed platform. The inclusion criteria were: (1) original articles; (2) studies in animal models where erythropoietin was administered; (3) studies where inflammation was studied and/or evaluated; (4) non-clinical studies in vivo with rodents; and (5) articles published in English. Results: A total of 36 articles met the criteria for qualitative analysis. Exogenous erythropoietin was used in models of sepsis, traumatic brain injury, and autoimmune neuritis with anti-inflammatory effects. The average dose of exogenous erythropoietin was 3000 IU/kg of weight. Erythropoietin was associated with a significant reduction of biomarkers such as immune-related effectors, cytokines, reactive oxygen species, and prostaglandins. Erythropoietin analogues, such as ARA290 or carbamylated erythropoietin, have the crucial advantage of promoting the anti-inflammatory effect without the thromboembolic risk by the proliferation of red blood cells. Conclusion: Erythropoietin is recognized as a multifunctional cytokine with anti-inflammatory properties, showing its significant effect both in acute and chronic murine models of inflammation.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	Silva I, Alípio C, Pinto R, Mateus V. Erythropoietin in animal models of inflammation. In: Gastro-Hepato 2021 - Virtual Global Congress on Advances in Gastroenterology and Hepatology, May 24-25, 2021.	pt_PT
dc.identifier.uri	http://hdl.handle.net/10400.21/17994
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.relation	IPL/2020/cEPO_ESTeSL	pt_PT
dc.relation.publisherversion	https://gastroenterology.peersalleyconferences.com/2021/program	pt_PT
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	pt_PT
dc.subject	Bowel inflammatory disease	pt_PT
dc.subject	Erythropoietin	pt_PT
dc.subject	FCT_UIDB/05608/2020	pt_PT
dc.subject	FCT_UIDP/05608/2020	pt_PT
dc.subject	IPL/2020/cEPO_ESTeSL	pt_PT
dc.title	Erythropoietin in animal models of inflammation	pt_PT
dc.type	conference object
dspace.entity.type	Publication
person.familyName	da Silva
person.familyName	Pinho Mateus
person.givenName	Inês Filipa Janeiro da Silva
person.givenName	Vanessa Alexandra
person.identifier.ciencia-id	C010-323F-3266
person.identifier.ciencia-id	5A12-571D-AD6A
person.identifier.orcid	0000-0001-7049-2512
person.identifier.orcid	0000-0002-3204-3772
rcaap.rights	openAccess	pt_PT
rcaap.type	conferenceObject	pt_PT
relation.isAuthorOfPublication	995e1831-ff5b-49e7-a6e3-8bc692212204
relation.isAuthorOfPublication	406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscovery	406041a5-682c-4f94-a4e2-ddbfc541313c